Foundayo Eligibility · Verified April 21, 2026
Who Qualifies for Foundayo? The Real 2026 Eligibility Rules
Last reviewed:
Sources: Foundayo US Prescribing Information, Eli Lilly, FDA, CMS, Ro, LillyDirect, Sesame Care. Published April 21, 2026.
Disclosure: Some links on this page are affiliate links. If you purchase through these links, we may earn a commission at no extra cost to you.
Here’s who qualifies for Foundayo in one sentence: adults 18 or older with a BMI of 30 or higher, or a BMI of 27 or higher who also have at least one weight-related medical condition like high blood pressure, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease.1 That’s the FDA-approved indication.
But that rule alone won’t tell you whether you’ll actually get a prescription. A handful of details in Lilly’s prescribing information change the answer — the two real contraindications, the “not recommended” situations, the medications that cap your dose, and the fact that Medicare’s new $50/month GLP-1 program does not currently cover Foundayo. We verified every detail on this page against Lilly’s prescribing information, CMS’s March 2026 FAQs, and current provider pricing.
| Your situation | What it probably means |
|---|---|
| Adult, BMI 30+, no history of thyroid cancer, not pregnant, not on another GLP-1 | Likely qualifies — move to eligibility check |
| Adult, BMI 27–29.9 with at least one weight-related condition | Likely qualifies — move to eligibility check |
| On oral birth control, taking insulin/sulfonylurea, or on simvastatin | Read the medication section — you can likely still qualify with adjustments |
| Personal or family history of medullary thyroid carcinoma (MTC) or MEN 2 | Stop here — Foundayo is contraindicated |
| Currently pregnant, breastfeeding, already on another GLP-1, or severe gastroparesis/liver impairment | Not appropriate right now — read on for details |
See if you qualify for Foundayo on Ro
$39 first month, then as low as $74/mo with annual prepay. Medication from $149/mo cash, or as low as $25/mo with a commercial insurance savings card. Decision typically within 2 days.
Check my Foundayo eligibility on Ro →Not sure Foundayo fits your situation? Take our free 60-second GLP-1 matching quiz → and we’ll route you to the pathway that actually matches your goals and medical history.
Why this page is different
Most top-ranking pages on this query do one of three things wrong. A few get the molecule itself wrong — we’ve seen pages claim Foundayo contains semaglutide. It doesn’t. Foundayo is the brand name for orforglipron, a small-molecule non-peptide GLP-1 receptor agonist from Eli Lilly, FDA-approved on April 1, 2026.2 That’s a different molecule than semaglutide (Wegovy, Ozempic, Wegovy pill) and a different molecule than tirzepatide (Zepbound, Mounjaro).
Others hand you a BMI bullet and stop. And a third group is owned by telehealth companies selling Foundayo access, so anything that might cost them a conversion gets buried. We’re not a telehealth company. We’re The RX Index — a pricing intelligence and comparison resource for GLP-1 telehealth providers. Our job is showing you whether you qualify, what could block you, and the fastest legitimate next step. If you don’t qualify, we route you to a better fit.
The short answer: who qualifies for Foundayo?
Foundayo is FDA-approved for adults with obesity, or adults with overweight plus at least one weight-related medical condition, alongside a reduced-calorie diet and increased physical activity.1 Two eligibility tracks, one goal: chronic weight management in adults.
Track 1 — obesity: BMI 30 or higher
If your body mass index is 30 or higher, you meet the clinical threshold for obesity and you don’t need a comorbidity to qualify. BMI is weight in kilograms divided by height in meters squared. At 5’6” and 186 lbs, your BMI is about 30.0. At 5’10” and 209 lbs, your BMI is about 30.0. Same threshold, round numbers.
Track 2 — overweight plus a weight-related condition: BMI 27 or higher
If your BMI is 27 to 29.9, you can still qualify — but you also need at least one weight-related medical condition. The FDA-approved label uses the phrase “weight-related comorbid condition” rather than a fixed list, so prescribers interpret it using standard obesity medicine practice.1 In Lilly’s published patient materials, the examples that consistently appear are:
| Qualifying condition | How it’s typically diagnosed |
|---|---|
| Hypertension (high blood pressure) | Blood pressure at or above 130/80 mmHg on multiple readings, or currently on blood pressure medication |
| Type 2 diabetes | A1C of 6.5% or higher on two tests, fasting glucose of 126 mg/dL or higher, or on a diabetes medication |
| Dyslipidemia | High LDL, high triglycerides, or low HDL |
| Obstructive sleep apnea | Diagnosed via sleep study, with or without CPAP use |
| Cardiovascular disease | Prior heart attack, stroke, coronary artery disease, or heart failure |
Some prescribers also consider non-alcoholic fatty liver disease, PCOS, and severe osteoarthritis related to weight. That’s clinical judgment, not a published list.
What if your BMI is on the edge?
A single BMI point can be the difference between “automatic yes” and “needs a conversation.” A BMI of 29.9 with hypertension qualifies on paper; a BMI of 26.9 with the same condition doesn’t. In reality, prescribers vary. If you’re in that gray zone, the fastest way to get a real answer is to start an eligibility check with a provider who does a full clinical review instead of just running an intake form.
Start a Foundayo eligibility check on Ro
A licensed clinician reviews your full picture. Decision typically within 2 days.
Start my eligibility check on Ro →The two real contraindications (hard stops)
Foundayo’s FDA-approved label has two contraindications. These are the situations where the medication must not be used at all:1
- 1.Personal or family history of medullary thyroid carcinoma (MTC), or a diagnosis of Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). This is the boxed warning on every GLP-1 receptor agonist sold in the US. Foundayo itself did not cause thyroid tumors in rodent studies (unlike peptide GLP-1s), but the class warning still applies.
- 2.A prior serious hypersensitivity reaction (like anaphylaxis or angioedema) to orforglipron or any of the inactive ingredients in Foundayo.
Those are the formal contraindications. Two more situations aren’t contraindications but work like them in practice:
- •Adults only. Foundayo’s safety and effectiveness have not been established in pediatric patients. It’s approved for adults 18 and older.1
- •Prior serious allergic reaction to a different GLP-1. This isn’t an automatic contraindication in the label, but it’s a caution flag — most prescribers will want extra history and monitoring, and some will decline.
The honest tradeoff (and why Foundayo is still the right call for a large group of readers)
Foundayo is not the most effective GLP-1 on the market. In the ATTAIN-1 trial, patients on the highest Foundayo dose who stayed on treatment lost an average of 12.4% of body weight over 72 weeks.3 That’s meaningful. But Zepbound (tirzepatide) — a weekly injection from the same manufacturer — has delivered over 20% average weight loss in trial averages. The Wegovy pill sits slightly ahead of Foundayo too.
If your top priority is maximum weight loss and you’re comfortable with a weekly injection, Zepbound is the harder-hitting option. See our Zepbound comparison →
But that’s the whole point. Foundayo delivers three things nothing else on the US market combines: it’s an FDA-approved oral GLP-1 (not a compounded peptide, not an injection), it’s the only oral GLP-1 that can be taken any time of day with or without food or water,2 and at $149/month cash for the starter dose, it’s meaningfully cheaper than branded injectable GLP-1s. Wegovy’s US list price sits at $1,349.02 per month; Zepbound at $499+. For readers who want an oral pill, a flexible schedule, and an FDA-approved product without an injection — Foundayo is the answer, and the weight-loss tradeoff is worth knowing about but not automatically disqualifying.
Cleared both contraindications? Check eligibility and pricing on Ro. Ro also runs a free GLP-1 Insurance Coverage Checker if you just want to see what your plan covers.
Check eligibility and coverage on Ro →“Not recommended” and “not right now” situations
Five situations aren’t formal contraindications, but they change whether Foundayo is appropriate at this point in your life. Some are permanent “not recommended” per the label. Others are “not right now” and you can revisit when the situation changes.
Severe gastroparesis — not recommended
Not recommendedFoundayo slows gastric emptying. That's part of how it works. In patients who already have severe gastroparesis (delayed stomach emptying), adding a medication that slows it further isn't recommended per the prescribing information.¹ Mild or moderate gastroparesis is a gray zone a prescriber evaluates case by case. Severe gastroparesis is a “don’t.”
Severe hepatic impairment — not recommended
Not recommendedFoundayo isn’t recommended for patients with severe liver impairment.¹ Mild to moderate liver issues are generally acceptable with prescriber oversight, but your prescriber needs your full history.
Pregnancy — discontinue if pregnant
Pause — not permanentFoundayo may cause fetal harm according to animal reproduction studies cited in the prescribing information. Lilly’s guidance is to discontinue Foundayo when pregnancy is recognized.¹ There’s a pregnancy exposure registry at 1-800-545-5979. If you’re actively trying to conceive, most prescribers pause the conversation until after pregnancy and breastfeeding.
Breastfeeding — not recommended
Pause — not permanentIt’s unknown whether orforglipron passes into human milk. Lilly recommends against using Foundayo while breastfeeding.¹ Not a permanent disqualifier — just a pause.
Already on another GLP-1 — switch, don’t stack
Switch, don't stackYou cannot take Foundayo on top of Wegovy, Ozempic, Zepbound, Mounjaro, Rybelsus, or the Wegovy pill. Concomitant use of two GLP-1 receptor agonists is not recommended.¹ But switching is common. Switching between GLP-1s has its own playbook — timing, washout windows, dose equivalencies — and it’s something your prescriber handles.
See our GLP-1 switching guide →Medications and conditions your prescriber needs to know about
These don’t disqualify you from Foundayo, but each one changes something — your backup contraception, your simvastatin dose, your maximum Foundayo dose, or your monitoring plan. A prescriber handles all of these cleanly if you flag them upfront.
Oral birth control — plan for backup
Action requiredFoundayo’s delayed gastric emptying can reduce the reliability of oral contraceptives, especially during initiation and dose escalation. Lilly’s guidance: if you take oral birth control pills, switch to a non-oral method, or add a barrier method (like condoms), for 30 days after starting Foundayo and for 30 days after each dose increase.¹ If you can’t or won’t change your birth control routine during titration, Foundayo may not be the right fit.
Simvastatin — cap at 20 mg daily
Dose adjustmentIf you take simvastatin for high cholesterol, do not exceed 20 mg once daily while on Foundayo.¹ Orforglipron raises simvastatin exposure. Your prescriber can dose-adjust or switch you to another statin without this interaction.
Strong CYP3A4 inhibitors — Foundayo capped at 9 mg
Dose cap or avoidStrong CYP3A4 inhibitors (the example in Lilly’s interaction table is clarithromycin) raise orforglipron blood levels. If you’re on one of these, your maximum Foundayo dose is capped at 9 mg per day.¹ There’s also a separate rule for drugs that inhibit both CYP3A4 and the OATP1B transporter (cyclosporine is the example in the label). In that combination, avoid Foundayo entirely.¹
Insulin or sulfonylureas — expect a dose adjustment
Dose adjustment + monitoringFoundayo lowers blood glucose. Combining it with insulin or a sulfonylurea (glimepiride, glipizide, glyburide) raises the risk of hypoglycemia. In Lilly’s Trial 2 in adults with type 2 diabetes, 7% of patients on Foundayo plus a sulfonylurea reported hypoglycemia, compared with 0.5% of patients not on a sulfonylurea.¹ Your prescriber will likely reduce your insulin or sulfonylurea dose when you start Foundayo and monitor closely.
Planned surgery under general anesthesia or deep sedation
Disclose to surgical teamFoundayo delays gastric emptying, which raises the risk of pulmonary aspiration during anesthesia. The prescribing information notes that current data are insufficient to recommend a fixed pause schedule or modified fasting instructions.¹ Tell your surgical team any time you have a planned surgery or procedure, and let them make the call.
Disclose-and-monitor situations
The following don’t change your eligibility on their own, but your prescriber needs to know about them:
- •History of pancreatitis — class-level risk; prescribers weigh benefits and risks, and discontinue Foundayo immediately if pancreatitis is suspected
- •Diabetic retinopathy — monitor for progression while on Foundayo
- •Severe kidney impairment or prior volume depletion events — monitor renal function if adverse reactions could cause dehydration
Before your visit: the Foundayo eligibility checklist
Bring this to your telehealth intake or in-person visit. The more complete the information, the faster the decision.
Your numbers
- □Current height and weight (BMI will be calculated from these)
- □Blood pressure reading in the last 3 months (if available)
- □A1C in the last 6 months (if diabetic or prediabetic)
Your medical history
- □Any personal or family history of medullary thyroid carcinoma (MTC)
- □Any diagnosis of Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- □Any prior serious allergic reaction to orforglipron, any GLP-1, or any medication excipient
- □Any history of pancreatitis, gallbladder disease, diabetic retinopathy, gastroparesis, severe kidney impairment, or severe liver impairment
- □Any planned surgeries or procedures requiring anesthesia
Your medications
- □Full list: prescriptions, over-the-counter, supplements, herbal products
- □Flag any of: oral birth control, simvastatin, clarithromycin (or other strong CYP3A4 inhibitors), cyclosporine, insulin, sulfonylureas (glimepiride, glipizide, glyburide), any current or recent GLP-1
Your pregnancy and reproductive status
- □Currently pregnant, trying to conceive, or breastfeeding
- □Oral contraceptive status (if applicable)
- □Commercial insurance card, Medicare ID, or Medicaid ID
Bring this list and your visit will take half the time.
Book your Foundayo eligibility check on Ro →How to actually get Foundayo (the four authorized channels)
If you qualify, Foundayo is available through four primary authorized channels: Ro (telehealth with insurance concierge), Sesame Care (telehealth with a lower program fee), LillyDirect (direct-fill if you already have a prescription), and Amazon Pharmacy (fulfillment if you already have a prescription). Every one of them requires a prescription.
Verified access channels — all-in monthly comparison
Last verified April 21, 2026. Prices and terms change; re-verify before you click. Pricing shown is for starting dose (0.8 mg); higher doses cost more on every channel.
| Channel | Medication price (starter) | Program / membership fee | All-in first month | Lowest w/ commercial insurance | Who handles eligibility |
|---|---|---|---|---|---|
| Ro | $149/mo (starter dose) | $39 first month, then as low as $74/mo annual prepay or $149/mo monthly | $188 first month ($149 med + $39 membership) | Medication as low as $25/mo | Ro's licensed clinicians; decision typically within ~2 days |
| Sesame Care | $149/mo (starter dose) | $59/mo (annual) or $99/mo (month-to-month) | $208 first month ($149 med + $59 annual); $248 month-to-month | Medication as low as $25/mo | Sesame providers; subscription includes messaging and labs at Quest in most states |
| LillyDirect | $149/mo (starter dose) | None | $149 first month (med only) | $25/mo with savings card | Not a prescribing channel — bring your own prescription |
| Amazon Pharmacy | $149/mo (starter dose, Lilly coupon auto-applied) | None | $149 first month (med only) | $25/mo with coverage | Not a prescribing channel — bring your own prescription |
Ro — best for insurance support + one-stop service
The Ro Body membership buys you access to a licensed clinician, ongoing care messaging, and Ro’s insurance concierge team, which handles prior-authorization paperwork for you. If your clinician decides Foundayo isn’t the right medication after the evaluation, they can pivot you to another FDA-approved GLP-1 on Ro’s formulary without a second intake. Ro also carries Wegovy pill, Wegovy pen, Zepbound pen, and Zepbound KwikPen.
Start on Ro: $39 first month, then as low as $74/mo →Sesame Care — best for lower recurring program fees
The $59/mo annual subscription undercuts Ro’s annual-prepay rate on the program side, though the medication price is the same. Labs are included at Quest in most states, and the subscription supports HSA/FSA reimbursement workflows.
Check Foundayo on Sesame Care →LillyDirect — best if you already have a prescription
No program fee, no subscription, same $25/mo floor with a commercial savings card. LillyDirect’s care-finder tool can help you find a prescriber through Healthgrades if you need one, but the prescribing itself happens outside the LillyDirect fulfillment flow. Prescriptions are fulfilled through Gifthealth and Walmart Pharmacy.
For our full provider comparison across every FDA-approved GLP-1 access channel, see our best Foundayo providers page →
What Foundayo actually costs
Foundayo’s cash price ranges from $149/month (starter dose) to $349/month (highest doses without the manufacturer’s refill program). With a commercial insurance savings card, the cost can drop to as low as $25/month.5,6
Dose-by-dose cash price ladder
| Foundayo dose | Cash price per month |
|---|---|
| 0.8 mg (starting dose) | $149 |
| 2.5 mg | $199 |
| 5.5 mg | $299 |
| 9 mg | $299 |
| 14.5 mg | $299 with Self-Pay Journey Program (45-day refill), $349 without |
| 17.2 mg | $299 with Self-Pay Journey Program (45-day refill), $349 without |
The 45-day refill rule catches a lot of readers
At the two highest doses (14.5 mg and 17.2 mg), the $299/month price requires refilling within 45 days of the previous fill. Miss the window, and the price jumps to $349/month. Ro and LillyDirect both send refill reminders as the deadline approaches.
Commercial insurance + the Foundayo Savings Card
If you have commercial insurance that covers Foundayo, the Foundayo Savings Card can drop your monthly cost to as low as $25.9 The card gives a maximum savings of $100 off a one-month fill, $200 off two months, or $300 off three months, usable up to 10 times per year. If your plan doesn’t cover Foundayo but you still have commercial insurance, the card caps your cost at $149 (0.8 mg), $199 (2.5 mg), or $299–$349 (higher doses).
A detail Lilly’s fine print makes explicit: you can’t seek HSA, FSA, or other reimbursement account reimbursement for amounts already covered by the savings card.9 Any out-of-pocket portion you actually pay remains HSA/FSA eligible. Confirm with your plan administrator. The savings card expires December 31, 2026, and is not available to patients with Medicare, Medicaid, Tricare, or any government insurance.
Medicare and Foundayo — the correction almost every page gets wrong
CMS announced two separate programs in December 2025: the Medicare GLP-1 Bridge (a short-term demonstration running July 1 through December 31, 2026) and the BALANCE Model (a longer-term program launching for Medicare Part D in January 2027).10,11
The Medicare GLP-1 Bridge covers only two medications as of CMS’s March 2026 FAQs: Wegovy (injection and pill) and Zepbound. Foundayo is not currently on the Bridge list.10,12 That means if you’re a Medicare Part D beneficiary in the second half of 2026, you can get Wegovy or Zepbound for a flat $50/month copay through the Bridge (if you meet the clinical criteria), but you cannot use the Bridge for Foundayo.
Medicare GLP-1 Bridge eligibility (for Wegovy or Zepbound, not Foundayo)
- •Enrolled in a Medicare Part D plan (standalone PDP or MA-PD) for 2026
- •Prior authorization submitted by your prescriber to CMS's central processor
- •Prescribed for weight reduction and ongoing weight maintenance
- •BMI ≥35 alone, OR
- •BMI ≥30 plus heart failure with preserved ejection fraction (HFpEF), uncontrolled hypertension despite two antihypertensive medications, or chronic kidney disease stage 3a or higher, OR
- •BMI ≥27 plus prediabetes, prior myocardial infarction, prior stroke, or symptomatic peripheral artery disease at the time GLP-1 therapy was initiated
The Bridge’s $50 copay does not count toward your Part D out-of-pocket cap, and Part D Low-Income Subsidy cost-sharing doesn’t apply to Bridge claims.
For the full Bridge breakdown, see our Medicare GLP-1 Bridge explainer →
If you want Foundayo specifically under Medicare in 2026, your practical options are:
- •Pay cash through LillyDirect, Ro (as a self-pay member), Sesame, or Amazon Pharmacy — starting at $149/month
- •Wait for the BALANCE Model rollout in January 2027 and confirm whether Foundayo has been added by then
- •Talk to your prescriber about whether Wegovy pill, Wegovy injection, or Zepbound (all covered on the Bridge) might be appropriate for your situation
Medicaid coverage for weight-loss GLP-1s varies state by state and is expected to expand through the BALANCE Model starting as early as May 2026 in states that opt in. Call your state Medicaid office or managed care plan for current formulary status.
If you don’t qualify for Foundayo, here’s what to do instead
Not qualifying for Foundayo doesn’t mean you’re out of options. The right alternative depends on why you didn’t qualify.
If you were disqualified on BMI
If your BMI is below 27, most telehealth platforms won’t prescribe any GLP-1 for weight loss. That’s the FDA indication. This is the lane where readers often get pushed toward unregulated “peptide” sellers online — which is exactly where we don’t want you going. Those sources have no pharmacy oversight, unknown sourcing, no clinical evaluation, and no recourse if something goes wrong. If you want to pursue weight management at a lower BMI, the right move is a clinician-led conversation about lifestyle changes, non-GLP-1 prescription options where appropriate, and bariatric consultation if it applies to you.
If you have a contraindication (MTC, MEN 2, prior serious hypersensitivity to orforglipron)
Foundayo and every other GLP-1 receptor agonist — Wegovy, Ozempic, Zepbound, Mounjaro, Rybelsus, Wegovy pill — carry the same boxed warning and class-level contraindications for MTC and MEN 2. If you have a history of either, none of the GLP-1 class is appropriate, and you should discuss non-GLP-1 options with your doctor.
If you’re already on another GLP-1
You’re in the largest and most common “not right now” lane. Switching between GLP-1s is a standard conversation — especially as people move from compounded formulations to FDA-approved branded options. Don’t stop your current medication cold without a prescriber plan.
Read our GLP-1 switching guide →If you’re pregnant, breastfeeding, or planning to be
Bookmark this page. Foundayo will still exist when you’re ready. In the meantime, discuss with your OB whether any weight management conversation is appropriate during your pregnancy or postpartum.
Still not sure what fits? Take our free 60-second GLP-1 matching quiz. We’ll ask about your goals, insurance status, medication list, and lifestyle preferences, then route you to the FDA-approved pathway that actually fits your situation.
Take our free 60-second GLP-1 matching quiz →What we actually verified
| What we verified | Source | Date checked |
|---|---|---|
| FDA indication, contraindications, warnings, drug interactions, dosing | Foundayo US Prescribing Information (pi.lilly.com) | Apr 21, 2026 |
| Trial weight-loss results (ATTAIN-1, 72 weeks) | Eli Lilly press release, April 1, 2026; AJMC coverage | Apr 21, 2026 |
| Ro Foundayo medication price, Ro Body membership pricing, insurance concierge, formulary | ro.co/weight-loss/foundayo and ro.co/press/foundayo | Apr 21, 2026 |
| LillyDirect Foundayo pricing, 45-day refill rule, savings card terms, HSA/FSA limitation, fulfillment partners | lilly.com/lillydirect/medicines/foundayo and Foundayo full terms | Apr 21, 2026 |
| Sesame Care Foundayo access and Success by Sesame subscription pricing | sesamecare.com | Apr 21, 2026 |
| Amazon Pharmacy same-day delivery and cash pricing | Amazon press release, April 9, 2026 | Apr 21, 2026 |
| Medicare GLP-1 Bridge eligibility, covered drugs (Wegovy and Zepbound only as of March 2026), $50 copay, dates | CMS Medicare GLP-1 Bridge FAQ (cms.gov) | Apr 21, 2026 |
| BALANCE Model dates (Medicaid May 2026, Medicare January 2027) | CMS BALANCE Model page | Apr 21, 2026 |
| Wegovy and Zepbound US list prices | Reuters, April 1, 2026 | Apr 21, 2026 |
Pricing and program terms change. We re-verify this page monthly for the first six months after publication, then quarterly.
Frequently asked questions
- Can I take Foundayo if I don't have diabetes?
- Yes. Foundayo is FDA-approved for adults with obesity, or adults with overweight plus at least one weight-related condition — which can be hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease, not just type 2 diabetes. You do not need to have diabetes to qualify.
- Do I need to have tried another GLP-1 first?
- No. Foundayo is a first-line option. You don't need to have failed Wegovy, Ozempic, Zepbound, or any other GLP-1 before qualifying.
- Can I take Foundayo and Wegovy (or Zepbound) at the same time?
- No. Concomitant use with another GLP-1 receptor agonist is not recommended per the Foundayo prescribing information. If you're currently on another GLP-1 and want to switch to Foundayo, your prescriber handles the transition.
- Does Foundayo really have no food or water restrictions?
- Yes. Foundayo is the only FDA-approved oral GLP-1 that can be taken any time of day, with or without food, with no water restriction. That's different from the Wegovy pill (oral semaglutide), which must be taken first thing in the morning with no more than 4 ounces of water, followed by a 30-minute fast before eating, drinking, or taking other medications.
- How fast can I get Foundayo after I'm approved?
- On Ro, most patients receive an eligibility decision within about 2 days. LillyDirect began shipping Foundayo on April 6, 2026. Amazon Pharmacy announced same-day delivery in roughly 3,000 cities on April 9, 2026.
- Can I use HSA or FSA funds for Foundayo?
- Foundayo is a prescription medication, which makes it generally HSA and FSA eligible like other prescription drugs. The one limitation: Lilly's savings-card terms say you can't seek HSA/FSA reimbursement for amounts already covered by the savings card itself. Any out-of-pocket portion you actually pay is eligible. Confirm details with your plan administrator.
- Is there a generic orforglipron?
- No. Orforglipron is under patent, and Foundayo is the only brand name approved for sale in the US.
- How is Foundayo different from Zepbound?
- Both are made by Eli Lilly, but they're different molecules. Zepbound (tirzepatide) is a weekly injection that targets both GLP-1 and GIP receptors and delivers higher average weight loss. Foundayo (orforglipron) is a once-daily pill that targets only GLP-1 and delivers somewhat lower average weight loss. Different molecule, different format, different weight-loss profile.
- Can I take Foundayo long-term?
- Yes. Foundayo is approved for chronic weight management, meaning long-term use. Like other GLP-1s, stopping the medication often leads to weight regain, so most prescribers frame it as a long-horizon treatment.
- Does Medicare cover Foundayo?
- As of April 2026, the Medicare GLP-1 Bridge (July through December 2026) covers only Wegovy and Zepbound — Foundayo is not on the current Bridge list. Foundayo's inclusion in the longer-term BALANCE Model starting January 2027 in Medicare Part D is pending CMS confirmation. In the meantime, Medicare enrollees paying for Foundayo pay the cash price of $149 or more per month.
- What's the difference between Foundayo and the Wegovy pill?
- Both are oral GLP-1s approved for weight management. Foundayo is orforglipron (a small-molecule non-peptide) and can be taken any time of day with or without food. The Wegovy pill is oral semaglutide (a peptide) and must be taken first thing in the morning with minimal water and a 30-minute fast before eating or drinking. Cash pricing is similar for both. Convenience is the biggest practical difference.
Your fastest legitimate next step
If you likely qualify and want insurance help
Check Foundayo eligibility on Ro. Decision typically within 2 days. Medication from $149/mo cash, as low as $25/mo with commercial insurance + the Foundayo Savings Card. Ro’s free GLP-1 Insurance Coverage Checker runs a benefits check if you want your numbers before you commit. $39 first month, then as low as $74/mo with annual plan.
Check Foundayo eligibility on Ro →If you likely qualify and want a lower program fee
Start with Sesame Care. $59/mo annual subscription. Medication at the same $149/mo floor. Labs at Quest included in most states. HSA/FSA reimbursement supported.
Start with Sesame Care →If you’re not sure Foundayo is your best fit
Take our free 60-second GLP-1 matching quiz. We’ll show you the pathway that actually fits your goals and medical history.
Take our free 60-second GLP-1 matching quiz →Related guides on The RX Index
- Best Foundayo providers (2026) →
- Best Foundayo providers that accept insurance →
- How to get Foundayo online: the legitimate path →
- What Foundayo costs without insurance (2026) →
- Foundayo Savings Card: eligibility and how it works →
- Does insurance cover Foundayo? →
- Does Medicare cover Foundayo? →
- Does Medicaid cover Foundayo? →
- Foundayo reviews: what patients report →
- The Medicare GLP-1 Bridge program explained →
- Zepbound vs Wegovy: 2026 comparison →
- How to switch from compounded semaglutide to a branded GLP-1 →
Sources
- Foundayo (orforglipron) US Prescribing Information, Eli Lilly and Company, April 2026. pi.lilly.com/us/foundayo-uspi.pdf
- “FDA approves Lilly’s Foundayo (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions,” Eli Lilly press release, April 1, 2026.
- ATTAIN-1 Phase 3 trial results, Eli Lilly press release, April 1, 2026; AJMC, April 2026.
- Reuters, “Pricing and availability of Novo, Lilly’s weight loss drugs,” April 1, 2026.
- Ro.co — Foundayo product page, Foundayo cost page, and press release, April 9, 2026.
- LillyDirect Foundayo page (lilly.com/lillydirect/medicines/foundayo) and Foundayo full terms.
- Sesame Care weight-loss program page (sesamecare.com/service/online-weight-loss-program).
- Amazon Pharmacy Foundayo launch announcement, April 9, 2026.
- Foundayo Savings Card terms and conditions, foundayo.lilly.com/coverage-savings.
- CMS, “Medicare GLP-1 Bridge” FAQ page, updated March 2026.
- CMS, “BALANCE Model” page.
- ReedSmith, “CMS Provides Details for Medicare GLP-1 Bridge Coverage,” March 9, 2026.
- KFF, “What Medicare’s Temporary Program Covering GLP-1s for Obesity Means for Beneficiaries,” March 2026.
By The RX Index Editorial Team. The RX Index is a pricing intelligence and comparison resource for GLP-1 telehealth providers. Published April 21, 2026. Last verified: April 21, 2026. Next scheduled review: May 21, 2026.
Affiliate disclosure: The RX Index may earn a commission if you start a program through some of our links. This does not change your price, and it does not change which providers we recommend.
Medical disclaimer: This page is for educational purposes only and is not medical advice. A licensed prescriber makes all final eligibility and treatment decisions.